Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO), a Delaware corporation, filed this Form 8-K on June 2, 2025, to report the entry into a material definitive agreement. The Company is an emerging growth company focused on therapeutic development, with principal executive offices in Waltham, Massachusetts.
Key Financial Metrics and Capital Structure
- Offering Proceeds: The Company estimates net proceeds of approximately $46.6 million from the underwritten public offering, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Potential Additional Proceeds: If all Series B and Series C warrants are exercised in cash at their exercise price, the Company could receive an additional gross $100.0 million.
- Offering Price: The combined offering price for each unit (pre-funded warrant plus Series A, B, and C warrants) is $0.7499.
- Shares Underlying Warrants: The offering involves pre-funded warrants and Series A, B, and C warrants to purchase 66,676,000 shares of common stock each.
- Liquidity and Runway: Based on current plans, existing cash plus the $46.6 million net proceeds is estimated to fund operating expenses and capital expenditures through the end of the third quarter of 2026. This estimate excludes potential payments from existing collaboration agreements with AbbVie Group Holdings Limited and Gilead Sciences, Inc.
Material Changes and Transaction Details
The primary material change is the execution of an underwriting agreement with Leerink Partners LLC for a complex capital raise involving multiple warrant classes:
- Pre-funded Warrants: Exercisable immediately for cash or on a cashless basis; exercise price is $0.0001 per share.
- Series A Warrants: Exercise price of $0.75 per share. Exercisable on the earlier of December 1, 2025, or five consecutive trading days where the stock price exceeds $1.50. Expires June 5, 2030, or upon exercise of the corresponding pre-funded warrant prior to December 1, 2025.
- Series B Warrants: Exercise price of $0.75 per share. Exercisable on or after November 1, 2025. Expires December 2, 2025, with potential reset and extension to December 31, 2025, if the stock price is below the exercise price.
- Series C Warrants: Exercise price of $0.75 per share. Exercisable on or after June 1, 2026. Expires December 2, 2026, with similar reset provisions as Series B.
- Offset and Cancellation: Series B and C warrants are subject to dollar-for-dollar offset against non-dilutive capital (e.g., collaboration payments, equity issuances above $1.50) received between issuance and December 1, 2026, provided at least $20 million in such capital is received.
- Minimum Price Floor: Future equity issuances between issuance and December 1, 2026, are subject to a minimum purchase price of $1.50 per share, reducible to $1.00 if a majority of pre-funded warrants are exercised before December 1, 2025.
Guidance, Outlook, and Risks
Outlook: Management anticipates the offering will close on or about June 5, 2025, subject to customary conditions. The capital raise is intended to extend the Company's cash runway to late 2026.
Risks and Contingencies:
- Authorized Shares: Exercisability is limited until stockholders approve an increase in authorized shares. If approval is not obtained by October 31, 2025, Series B warrant expiration is extended.
- Beneficial Ownership Limits: Holders are restricted from exercising if it would result in beneficial ownership exceeding 4.99% (or up to 19.99% with notice).
- Warrant Exercise Uncertainty: There is no assurance that warrants will be exercised for cash; they may expire unexercised.
- Forward-Looking Statements: The cash runway estimate is based on assumptions that may prove incorrect, and the Company could exhaust capital sooner than anticipated.
Investor Verification Checklist
- Verify the closing of the offering on or about June 5, 2025, and the actual net proceeds received.
- Monitor the status of the stockholder vote to increase authorized shares, required for full warrant exercisability.
- Track the Company's stock price relative to the $1.50 threshold, which triggers Series A exercisability and affects the minimum price floor for future issuances.
- Review future filings for any non-dilutive capital receipts that may trigger the offset and cancellation of Series B and C warrants.
- Confirm the actual cash runway as the Company progresses through 2025 and 2026, noting any deviations from the Q3 2026 estimate.